<DOC>
	<DOC>NCT00250575</DOC>
	<brief_summary>Clozapine is an antipsychotic. This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia. This study is not recruiting in the United States.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia</brief_title>
	<detailed_description>Clozapine is an antipsychotic. This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<criteria>Diagnosed as schizophrenia Not responded to at least two atypical antipshychotics launched in Japan Inpatient Low white blood cell count Significant heart diseases Diabetes mellitus Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Schizophrenia, treatment-resistant, clozapine</keyword>
</DOC>